参考文献/References:
[1] ARORA T,MULLANGI S,VADAKEKUT E S,et al.Epithelial ovarian cancer[DB/OL].2024-05-06/2024-12-06.
[2] 徐娟,王新梅,赵建国,等.卵巢癌患者抑郁状态相关因素及预后分析:一项回顾性研究[J].肿瘤预防与治疗,2024,37(5):434-438.
[3] 单冬勇,成树林,马邺晨,等.上皮性卵巢癌血清中肿瘤标志物水平及其临床意义[J].中南大学学报(医学版),2023,48(7):1039-1049.
[4] FEENEY L,HARLEY I J,MCCLUGGAGE W G,et al.Liquid biopsy in ovarian cancer:Catching the silent killer before it strikes[J].World J Clin Oncol,2020,11(11):868-889.
[5] 耿海慧,曹爱华.卵巢癌患者多种血清肿瘤标志物表达水平及其对疾病的诊断价值研究[J].陕西医学杂志,2022,51(7):886-889.
[6] 王小玉,韩凤娟.基于“天癸-肾阳-命门”学说探究卵巢癌发病机制[J].陕西中医,2021,42(9):1261-1263.
[7] GANDHI T,ZUBAIR M,BHATT H.Cancer antigen 125[DB/OL].2024-05-02/2024-12-06.
[8] FAN Q,LUO G,YI T,et al.Diagnostic value of urinary-to-serum human epididymis protein 4 ratio in ovarian cancer[J].Biomed Rep,2017,7(1):67-72.
[9] PARK H,LEE D W,KIM M J,et al.Low serum T3 levels are associated with false-positive results when using the risk of ovarian malignancy algorithm(ROMA)in women with benign ovarian disease[J].Taiwan J Obstet Gynecol,2021,60(1):36-40.
[10] 李松磊,秦娟娟,赵瑞,等.肿瘤标志物联合血常规炎性指标、凝血功能指标在上皮性卵巢癌诊断中的价值分析[J].标记免疫分析与临床,2024,31(6):1027-1032.
[11] 邹乔剑,姚书忠,陈怡李,等.铜与卵巢癌的研究进展[J].国际妇产科学杂志,2024,51(2):215-219.
[12] 黄山高,吴月玲,张颖.瞄准未来:卵巢癌靶向治疗的新进展[J].实用医学杂志,2024,40(14):1901-1907.
[13] 韩喜婷,朱继存.2006—2020年中国女性卵巢癌死亡率及寿命损失变化趋势[J].现代疾病预防控制,2023,34(7):481-485,494.
[14] 周诗杰,方珈文,姜雯.1990—2019年中国宫颈癌和卵巢癌疾病负担趋势及预测研究[J].中华肿瘤防治杂志,2024,31(11):662-669.
[15] TANHA K,MOTTAGHI A,NOJOMI M,et al.Investigation on factors associated with ovarian cancer:An umbrella review of systematic review and meta-analyses[J].J Ovarian Res,2021,14(1):153.
[16] KHANLARKHANI N,AZIZI E,AMIDI F,et al.Metabolic risk factors of ovarian cancer:A review[J].JBRA Assist Reprod,2022,26(2):335-347.
[17] 李佳旎,周雪影,李亚兰.卵巢癌患者发病危险因素及术后康复效果影响因素分析[J].中国卫生统计,2019,36(1):62-64.
[18] SANTOS M L,PAIS A S,ALMEIDA SANTOS T.Fertility preservation in ovarian cancer patients[J].Gynecol Endocrinol,2021,37(6):483-489.
[19] 李丹,张虹.卵巢癌发病机制与免疫治疗的临床研究进展[J].实用妇产科杂志,2020,36(12):908-911.
[20] 崔馨,徐娟,贾雪梅.恶性、交界性及良性卵巢肿瘤中生化指标的表达及鉴别诊断价值[J].广东医学,2024,45(11):1418-1424.
[21] LAHLOU N,BRUN J L.Ovarian tumor markers of presumed benign ovarian tumors[J].J Gynecol Obstet Biol Reprod(Paris),2013,42(8):752-759.
[22] ZONG X,YANG J X,ZHANG Y.Persistently elevated alpha-fetoprotein associated with chronic hepatitis B during chemotherapy for malignant ovarian germ cell tumors:A case series and a review of the literature[J].J Ovarian Res,2019,12(1):124.
[23] ZHANG M,CHENG S,JIN Y,et al.Roles of CA125 in diagnosis,prediction,and oncogenesis of ovarian cancer[J].Biochim Biophys Acta Rev Cancer,2021,1875(2):188503.
[24] ZHANG R,SIU M,NGAN H,et al.Molecular biomarkers for the early detection of ovarian cancer[J].Int J Mol Sci,2022,23(19):12041.
[25] LYCKE M,ULFENBORG B,MALCHAU LAUESGAARD J,et al.Consideration should be given to smoking,endometriosis,renal function(eGFR)and age when interpreting CA125 and HE4 in ovarian tumor diagnostics[J].Clin Chem Lab Med,2021,59(12):1954-1962.
[26] 杨海明,王克义,卓广超,等.人附睾蛋白4、糖类抗原125的联合检测和ROMA在卵巢癌鉴别诊断中的价值[J].中国卫生检验杂志,2022,32(10):1166-1169,1174.
[27] 黄倩,焦晋兰,尚钊源,等.血清HE4、CA125水平与ROMA指数联合诊断卵巢癌的价值[J].深圳中西医结合杂志,2023,33(15):58-60,137.
[28] 李军,南新营,刘书磊,等.CA125、HE4及ROMA指数对卵巢肿瘤的诊断价值[J].山西卫生健康职业学院学报,2023,33(6):2-4.
[29] GADDUCCI A,MULTINU F,COSIO S,et al.Clear cell carcinoma of the ovary:Epidemiology,pathological and biological features,treatment options and clinical outcomes[J].Gynecol Oncol,2021,162(3):741-750.
[30] 张晓蕾.HE4、血浆D-二聚体、FIB与血清CA125在卵巢上皮性肿瘤术前诊断中的价值[D].济宁:济宁医学院,2024.
相似文献/References:
[1]史阿娉,史成兴,杨志军,等.超声造影与彩色多普勒超声检查诊断卵巢肿瘤对比研究*[J].陕西医学杂志,2019,(5):628.
SHI Aping,SHI Chengxing,YANG Zhijun,et al.Comparative analysis of contrastenhanced ultrasound and color doppler ultrasound in the identification of ovarian tumors[J].,2019,(5):628.
[2]杨 勇,王 冰△.人绒毛膜促性腺激素、人附睾蛋白4、糖类抗原199联合检测对卵巢肿瘤的诊断价值[J].陕西医学杂志,2019,(8):1091.
YANG Yong,WANG Bing..The diagnostic value of β-HCG,HE4, CA199 joint detection for ovarian neoplasms[J].,2019,(5):1091.
[3]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(5):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[4]梁 媛,蔡江义,谢 云,等.DNA倍体分析联合血清肿瘤标志物筛查宫颈癌价值研究[J].陕西医学杂志,2021,50(10):1296.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.031]
[5]耿海慧,曹爱华.卵巢癌患者多种血清肿瘤标志物表达水平及其对疾病的诊断价值研究[J].陕西医学杂志,2022,51(7):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
GENG Haihui,CAO Aihua.Expression levels of various serum tumor markers in ovarian cancer patients and their diagnostic value for the disease[J].,2022,51(5):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
[6]赵 鹏,刘 冬,兰 飞,等.非小细胞肺癌化疗前后血清糖类抗原125、基质金属蛋白酶-9、可溶性程序性死亡配体1水平变化及其与疗效关系研究[J].陕西医学杂志,2022,51(12):1564.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.023]
ZHAO Peng,LIU Dong,LAN Fei,et al.Changes of serum CA125,MMP-9 and sPD-L1 levels before and after chemotherapy in non-small cell lung cancer and their relationship with therapeutic effect[J].,2022,51(5):1564.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.023]
[7]郭愿愿,党升强,崔立春,等.阿来替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌疗效及患者血清糖类抗原125和神经元特异性烯醇化酶表达水平对疗效的预测分析[J].陕西医学杂志,2023,52(10):1392.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.024]
[8]刘毅力,郭 冲,尹 恒,等.环状RNA circ-TAGLN在卵巢癌细胞中的表达及对卵巢癌细胞增殖和侵袭的影响[J].陕西医学杂志,2024,(2):147.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.001]
LIU Yili,GUO Chong,YIN Heng,et al.Expression of circular RNA circ-TAGLN in ovarian cancer and its effect on ovarian cancer cell proiferation and invasion[J].,2024,(5):147.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.001]
[9]王 静,张虹宇,张 磊,等.动脉灌注化疗联合细胞因子诱导杀伤细胞治疗晚期卵巢癌疗效及对患者血清癌胚抗原、糖类抗原125、可溶性B7-H4蛋白水平的影响[J].陕西医学杂志,2024,(2):199.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Efficacy of arterial infusion chemotherapy combined with CIK in the treatment of advanced ovarian cancer and its effect on serum levels of carcinoembryonic antigen,carbohydrate antigen 125 and soluble B7-H4 protein[J].,2024,(5):199.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]